Form 4: CRISPR Therapeutics Director Sandesh Mahatme Acquires Stock Options

Director Sandesh Mahatme acquired stock options for 13,000 common shares in CRISPR Therapeutics.

Summary

• Sandesh Mahatme, a director of CRISPR Therapeutics AG, acquired stock options on May 30, 2024.
• The options grant him the right to buy 13,000 common shares at an exercise price of $54.06.
• The options vest in 12 equal monthly installments starting May 31, 2024, with the final installment vesting no later than the 2025 Annual General Meeting of Shareholders or the one-year anniversary of the grant date.
• Following the transaction, Mahatme directly owns options for 13,000 common shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. It's a neutral-positive signal.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, similar to companies like Intellia Therapeutics and Editas Medicine.
• The vesting schedule of 12 months is also a common practice to ensure continued service and commitment from the recipient.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the director's interests with the company's long-term performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates